Amevive Side Effects
Generic name: alefacept
Note: This document contains side effect information about alefacept. Some of the dosage forms listed on this page may not apply to the brand name Amevive.
Some side effects of Amevive may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to alefacept: intramuscular powder for injection
Get emergency medical help if you have any of these signs of an allergic reaction while taking alefacept (the active ingredient contained in Amevive) hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using alefacept and call your doctor at once if you have a serious side effect such as:
-
fever, chills, body aches, flu symptoms, sores in your mouth and throat;
-
cough with yellow or green mucus, stabbing chest pain, wheezing, feeling short of breath;
-
nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
-
swelling, warmth, redness, itching, or oozing from the skin;
-
new skin lesions, or a sunburn-like skin rash; or
-
worsening or no improvement of your skin condition.
Less serious side effects of alefacept may include:
-
sore throat, cough;
-
dizziness;
-
mild nausea;
-
headache;
-
itching;
-
muscle pain;
-
pain or swelling where the medicine was injected.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to alefacept: intramuscular powder for injection, intravenous powder for injection
Immunologic
Immunologic side effects including dose-dependent reductions in circulating CD4+ and CD8+ T lymphocyte counts have been reported.
Cardiovascular
The total percentage of alefacept-treated patients hospitalized for cardiovascular events was 1.2%.
Cardiovascular side effects including coronary artery disorder (<1%) and myocardial infarction (<1%) have been the adverse reactions which most commonly resulted in clinical intervention.
Oncologic
Twenty five of the 1,357 patients who received alefacept (the active ingredient contained in Amevive) were diagnosed with a total of 35 treatment-emergent malignancies. Six cases were basal cell and seventeen cases were squamous cell cancers of the skin. Three cases of lymphoma have been reported; one was classified as non-Hodgkin's follicle-center cell lymphoma and two were classified as Hodgkin's disease.
Oncologic side effects including malignancies have been reported. Postmarketing reports of malignancies including skin, solid organ, lymphomas and leukemias have also been received.
General
Chills have been reported to occur predominantly with intravenous administration.
General side effects including chills (6%), dizziness, headache, and accidental injury have been reported. Postmarketing reports of sepsis and opportunistic infections (viral, fungal, and bacterial) have been received.
Local
Local side effects including injection site pain and injection site inflammation have been reported.
Gastrointestinal
Gastrointestinal side effects including nausea have been reported. Postmarketing reports of clostridium difficile colitis have been received.
Respiratory
Respiratory side effects including pharyngitis and increased cough have been reported. Postmarketing reports of pharyngitis have also been received.
Dermatologic
Dermatologic side effects including pruritus have been reported. Postmarketing reports of cellulitis have been received.
Musculoskeletal
Musculoskeletal side effects including myalgia have been reported.
Hepatic
Hepatic side effects including postmarketing reports of asymptomatic transaminase elevation, fatty infiltration of the liver, hepatitis, and severe liver failure have been received.
Genitourinary
Genitourinary side effects including postmarketing reports of urinary tract infection have been received.
More Amevive resources
- Amevive Prescribing Information (FDA)
- Amevive Monograph (AHFS DI)
- Amevive Advanced Consumer (Micromedex) - Includes Dosage Information
- Amevive Consumer Overview
- Amevive MedFacts Consumer Leaflet (Wolters Kluwer)
- Alefacept Professional Patient Advice (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.


